Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 217

1.

Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.

Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A.

Br J Dermatol. 2014 Feb;170(2):274-303. doi: 10.1111/bjd.12663. Review.

PMID:
24131260
2.

Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.

Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W.

Br J Dermatol. 2008 Sep;159(3):513-26. doi: 10.1111/j.1365-2133.2008.08732.x. Epub 2008 Jul 9. Review.

PMID:
18627372
3.

Biological treatments for moderate-to-severe psoriasis: indirect comparison.

Galván-Banqueri M, Marín Gil R, Santos Ramos B, Bautista Paloma FJ.

J Clin Pharm Ther. 2013 Apr;38(2):121-30. doi: 10.1111/jcpt.12044. Epub 2013 Feb 26.

PMID:
23442134
4.

Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.

Garber C, Creighton-Smith M, Sorensen EP, Dumont N, Gottlieb AB.

J Drugs Dermatol. 2015 Aug;14(8):881-6. Review.

PMID:
26267734
5.

[Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].

Zhang Z, Schmitt J, Wozel G, Kirch W.

Med Klin (Munich). 2009 Feb 15;104(2):125-36. doi: 10.1007/s00063-009-1024-8. Epub 2009 Feb 26. German.

PMID:
19242664
6.

Economic evaluation of systemic therapies for moderate to severe psoriasis.

Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH.

Br J Dermatol. 2009 Jun;160(6):1264-72. doi: 10.1111/j.1365-2133.2008.08962.x. Epub 2008 Dec 15.

PMID:
19120346
7.

Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points.

Puig L, López A, Vilarrasa E, García I.

J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1633-53. doi: 10.1111/jdv.12238. Epub 2013 Aug 19. Review.

PMID:
24033851
8.

Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response.

Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P.

Br J Dermatol. 2015 Feb;172(2):504-12. doi: 10.1111/bjd.13437. Epub 2015 Jan 21. Review.

PMID:
25288183
9.

Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.

Reich K, Burden AD, Eaton JN, Hawkins NS.

Br J Dermatol. 2012 Jan;166(1):179-88. doi: 10.1111/j.1365-2133.2011.10583.x. Epub 2011 Nov 11. Review.

PMID:
21910698
10.

Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment.

Lucka TC, Pathirana D, Sammain A, Bachmann F, Rosumeck S, Erdmann R, Schmitt J, Orawa H, Rzany B, Nast A.

J Eur Acad Dermatol Venereol. 2012 Nov;26(11):1331-44. doi: 10.1111/j.1468-3083.2012.04492.x. Epub 2012 Mar 9. Review. Erratum in: J Eur Acad Dermatol Venereol. 2012 Jul;26(7):930.

PMID:
22404617
11.

Interventions for nail psoriasis.

de Vries AC, Bogaards NA, Hooft L, Velema M, Pasch M, Lebwohl M, Spuls PI.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD007633. doi: 10.1002/14651858.CD007633.pub2. Review.

PMID:
23440816
12.

Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis.

Nast A, Jacobs A, Rosumeck S, Werner RN.

J Invest Dermatol. 2015 Nov;135(11):2641-2648. doi: 10.1038/jid.2015.206. Epub 2015 Jun 5. Review.

13.

Ustekinumab for the treatment of moderate to severe psoriasis.

Gospodarevskaya E, Picot J, Cooper K, Loveman E, Takeda A.

Health Technol Assess. 2009 Oct;13 Suppl 3:61-6. doi: 10.3310/hta13suppl3/10. Review.

PMID:
19846031
14.

Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.

Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P.

Adv Ther. 2012 Jul;29(7):620-34. doi: 10.1007/s12325-012-0035-7. Epub 2012 Jul 27.

PMID:
22843208
15.

Efficacy and safety of systemic treatments for psoriasis in elderly patients.

Piaserico S, Conti A, Lo Console F, De Simone C, Prestinari F, Mazzotta A, Gualdi G, Guarneri C, Borsari S, Cassano N.

Acta Derm Venereol. 2014 May;94(3):293-7. doi: 10.2340/00015555-1719.

16.

Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis.

Ferrándiz C, García A, Blasco AJ, Lázaro P.

J Eur Acad Dermatol Venereol. 2012 Jun;26(6):768-77. doi: 10.1111/j.1468-3083.2011.04357.x. Epub 2011 Nov 30.

PMID:
22126264
17.

Comparative efficacy of biologics in psoriasis: a review.

Kim IH, West CE, Kwatra SG, Feldman SR, O'Neill JL.

Am J Clin Dermatol. 2012 Dec 1;13(6):365-74. doi: 10.2165/11633110-000000000-00000. Review.

PMID:
22967166
18.

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).

Barker J, Hoffmann M, Wozel G, Ortonne JP, Zheng H, van Hoogstraten H, Reich K.

Br J Dermatol. 2011 Nov;165(5):1109-17. doi: 10.1111/j.1365-2133.2011.10615.x.

PMID:
21910713
19.

Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.

Garber C, Plotnikova N, Au SC, Sorensen EP, Gottlieb A.

J Drugs Dermatol. 2015 Aug;14(8):846-52.

PMID:
26267729
20.

Cost-effectiveness of systemic treatments for moderate-to-severe psoriasis in the German health care setting.

Küster D, Nast A, Gerdes S, Weberschock T, Wozel G, Gutknecht M, Schmitt J.

Arch Dermatol Res. 2016 May;308(4):249-61. doi: 10.1007/s00403-016-1634-y. Epub 2016 Mar 9.

PMID:
26961372

Supplemental Content

Support Center